KALA BIO, Inc.
No SEC Form 4 filings for $KALA in the last 30 days.
See all $KALA insider activity →KALA BIO received a Nasdaq notice that its stock failed to meet the $1.00 minimum bid price, violating a listing rule. The company is ineligible for the standard compliance period due to a recent reverse split and will request a hearing. The stock will remain listed pending the decision.
KALA BIO Inc. ( NASDAQ:KALA ) jumped 37.87% to $0.88 in after-hours trading on Tuesday. Check out the current price of KALA stock here. According to Benzinga Pro data, the stock closed the regular session at $0.64, up 3.45%.
Kala Bio Inc. ( NASDAQ: KALA ) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition. The company had a session volume of 14.04 million compared to the average volume of 216.47 thousand, according to data from Benzinga Pro.
Over the past 7 days, alphai's AI scored 1 news story mentioning KALA (KALA BIO, Inc.). Coverage has skewed bearish: 0 bullish, 0 neutral, and 1 bearish.
Recent KALA coverage spans financial news and corporate actions.
Potential suspension of trading pending hearing
KALA BIO experienced a nearly 38% increase in after-hours trading, likely driven by positive news or developments. The stock's sharp movement suggests increased investor interest, but the cause remains unspecified.
Kala Bio's stock experienced a sharp decline following the announcement of halted development of its experimental eye treatment, indicating negative market sentiment and potential future challenges.
Limited direct impact on Kala Bio (KALA) from the overall market rally; no specific news indicating company-specific catalysts.
Analysts' consensus suggests a significant upside potential of approximately 74.7% for KALA BIO, driven by increased earnings estimates and positive sentiment.
alphai scores every news story that mentions KALA with an AI model for sentiment and relevance, and aggregates insider trades from KALA BIO, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
KALA BIO received a Nasdaq notice that its stock failed to meet the $1.00 minimum bid price, violating a listing rule. The company is ineligible for the standard compliance period due to a recent reverse split and will request a hearing. The stock will remain listed pending the decision.
1 min readKALA BIO Inc. ( NASDAQ:KALA ) jumped 37.87% to $0.88 in after-hours trading on Tuesday. Check out the current price of KALA stock here. According to Benzinga Pro data, the stock closed the regular session at $0.64, up 3.45%.
3 min readKala Bio Inc. ( NASDAQ: KALA ) stock is down on Monday after the company halted development of its experimental treatment for a specific eye condition. The company had a session volume of 14.04 million compared to the average volume of 216.47 thousand, according to data from Benzinga Pro.
2 min readU.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 150 points on Monday. Following the market opening Monday, the Dow traded up 0.19% to 46,333.68 while the NASDAQ rose 0.67% to 22,635.76. The S&P 500 also rose, gaining, 0.42% to 6,671.51.
3 min readThe mean of analysts' price targets for KALA BIO (KALA) points to a 74.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
5 min readKala Bio ( NASDAQ:KALA ) , a clinical-stage biopharmaceutical company focused on novel therapies for eye diseases, released its second quarter 2025 results on August 8, 2025. The headline was a net loss per share of $1.71 ( GAAP ) . Marginally wider than the analyst estimate of $1.70 ( GAAP ) .
2 min read
